GlassScriptPhysician profile
Alvina Shaikh
NPI 1770120222
$6,022.67
in general payments reported to CMS, 2019-2025
30 companies · $999 in 2025
The $999 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $1,327 · 2023: $1,331 · 2024: $1,485 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,815.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,114.44 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Mylan Specialty L.P. | $808.94 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $745.42 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $718.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $713.52 | 2021-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $515.75 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $196.91 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $180.32 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $172.82 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.43 | 2021-2022 | |
| Exact Sciences Corporation | $133.42 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $106.95 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $49.11 | 2021-2025 | Doc Band |
| Sanofi Pasteur INC. | $48.75 | 2022-2025 | |
| Viatris Specialty LLC | $48.42 | 2025 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $34.50 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $33.70 | 2025 | Voquezna |
| Lundbeck LLC | $29.04 | 2024 | Rexulti |
| Gilead Sciences, INC. | $25.57 | 2025 | Yeztugo |
| Avanir Pharmaceuticals, INC. | $24.83 | 2022 | |
| Esperion Therapeutics, INC. | $21.61 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.89 | 2025 | Caplyta |
| Exeltis, USA INC. | $18.80 | 2024 | Slynd |
| Amgen INC. | $18.34 | 2024 | Repatha, Otezla |
| Seqirus USA INC | $17.67 | 2024 | Flucelvax, Fluad |
| Astellas Pharma US INC | $17.06 | 2025 | Veozah |
| Azurity Pharmaceuticals, INC. | $15.79 | 2023 | Edarbi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.50 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $15.01 | 2024 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvina Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.